Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults

This prospective, randomized, multicenter, parallel-group, non-inferiority study was conducted at 43 centers in the United States from August 2013 to April 2014. A non-inferior design was used because both products contain the same active components, and it was considered unethical to include a placebo arm. The study comprised an induction phase of 2 days and a stabilization phase of 20 days, with study visits scheduled on Days 1, 2, 3, 4, 8, 15, and 22. Eligible opioid-dependent patients were randomly assigned within 14 days of screening to induction with either the BNX sublingual tablets or generic buprenorphine tablets for 2 days. On Day 3, patients initially allocated to buprenorphine were switched to BNX film, whereas those allocated to BNX sublingual tablets continued on the same treatment. On Day 15, patients receiving BNX film were switched to BNX sublingual tablets, and those on BNX sublingual tablets were switched to BNX film. At the final study visit on Day 22, patients were offered the option of continuing in an open-label follow-up study of BNX sublingual tablets.

Inclusion criteria

• Male/female 18-65 years old
• Able to read, comprehend & sign the informed consent form
• Meet opioid dependence criteria in DSM-IV-TR the past 12 months
• Have a buprenorphine-negative UDS &/or urine dipstick
• Prepared to abstain from opioids other than the study drug & from other addictive drugs
• Negative urine pregnancy test
• Females of childbearing potential who use a reliable method of contraception. Females of non-childbearing potential; surgically sterile or post-menopausal as defined by being at least 50 years of age & having an absence of menses for at least 2 years
• Clearance from the prescribing MD to be withdrawn from their prescribed opioids for subjects receiving opioids for pain
• Lack of clinically significant abnormalities in health assessments performed at screening. Unclear cases should be approved by the medical monitor
• At least mild withdrawal symptoms (COWS ≥9)

Exclusion criteria

• Pregnant, lactating or planning to be pregnant during study
• Unwilling/unable to comply with the requirements of the protocol (e.g., pending incarceration) are in a situation/condition that may interfere with participation in the study
• Prescribed treatment with generic buprenorphine monotherapy within 90 days prior start of treatment
• Daily dose of methadone over 30 mg during the past week or who received the last dose of methadone less than 30 hours prior to treatment
• Participating in other clinical studies in which medications is delivered or who have used an investigational drug/device within the last 30 days
• Allergy, sensitivity or intolerance to BUP, NAL or any related drug; history of drug hypersensitivity or intolerance which, in the opinion of the investigator, would compromise the safety of the subject/study
• Staff, affiliated with, or family member of the staff directly involved with this study
• Serious untreated Axis I DSM-IV-TR psychiatric comorbidity (actively suicidal or homicidal, have untreated schizophrenia)
• Tongue/oral deformities that may affect the absorption of the drug products
• Current/history of clinically significant medical disorder or condition which would jeopardize the safety or impact the validity of the results. Unclear cases should be discussed with & approved by the medical monitor
• HIV-seropositive with a CD4+ count <200, active AIDS defining infection in the last 120 days
• Have Class III/IV congestive heart failure, symptomatic myocardial ischemia or history of long QT syndrome (or an immediate family member with this condition)
• Currently taking Class 1A antiarrhythmic medications (e.g., quinidine, procainamide, & disopyramide) or Class III antiarrhythmic medications (e.g., sotalol, amiodarone, & dofetilide)
• Have uncontrolled hypertension, pulse oximetry ≤92%or clinically significant abnormality on 12-lead ECG, including a corrected QT (QTc) interval >450 ms
• Severe liver disease